Sotagliflozin

Sotagliflozin

Clinical data
Trade names	Zynquista
Routes of administration	By mouth
ATC code	A10BK06 (WHO)
Legal status
Legal status	EU: Rx-only
Identifiers
CAS Number	1018899-04-1
PubChem CID	24831714
DrugBank	12713
ChemSpider	27289071
UNII	6B4ZBS263Y
KEGG	D10669
CompTox Dashboard (EPA)	DTXSID20144314
ECHA InfoCard	100.231.837
Chemical and physical data
Formula	C21H25ClO5S
Molar mass	424.94 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)SC)O)O)O)Cl
InChI InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1 Key:QKDRXGFQVGOQKS-CRSSMBPESA-N

Sotagliflozin, sold under the brand name Zynquista, is a drug approved in the European Union for people with type 1 diabetes.

The most common side effect is genital infection in women. Other common side effects include diabetic ketoacidosis, diarrhoea and genital infection in men.

The US Food and Drug Administration (FDA) refused its approval for use in combination with insulin for the treatment of type 1 diabetes. It is developed by Lexicon Pharmaceuticals.

Sotagliflozin is a combination sodium/glucose cotransporter 1 and 2 (SGLT1/2) inhibitor and is in the class of drugs known as gliflozins.

External links

• "Sotagliflozin". Drug Information Portal. U.S. National Library of Medicine.